-
How Paratope Refinement Can Mitigate Antibody Polyspecificity
Jul 3, 2019, 08:15 AM by Michael CroftFull storyBio-IT World | There is often a lack of understanding in drug discovery about how polyspecificity drives antibody toxicity. This shows polyspecificity is an underappreciated phenomenon in therapeutic antibody development, but that these unwanted properties can be fully improved by paratope refinement.
-
SEKISUI XenoTech Announces Enhanced Synergy in ADME Testing Services
Jul 2, 2019, 14:12 PM by Michael CroftKANSAS CITY, KS, UNITED STATES - Jul 2, 2019 - SEKISUI XenoTech is collaborating with the Drug Development Solutions Center to offer a full suite of nonclinical testing services specializing in the evaluation of Absorption, Distribution, Metabolism, and Excretion (ADME) in potential new drugsFull story -
MELLODDY Using Federated Learning To Improve Drug Development
Jul 2, 2019, 14:00 PM by Michael CroftFull storyBio-IT World | A 17-partner consortium in Europe is seeking to confirm the utility of a machine learning platform for better predicting promising compounds for drug development. The three-year initiative, which launched in June, represents the first large-scale deployment of blockchain technology to extract insights from multiple preclinical datasets without having to first pool the data.
-
MGI Responds to Illumina Lawsuits with Confidence in the Strength of its Patent Portfolio
Jul 2, 2019, 13:32 PM by Michael CroftSAN JOSE, CA - Jul 2, 2019 - MGI Responds to Illumina Lawsuits with Confidence in the Strength of its Patent PortfolioCalls for Fair Competition in the Gene Sequencing Market MGI, a subsidiary of BGI Group, expressed confidence in its core patent portfolio in the field of gene sequencing and vowed to fully support the industry to achieve higher quality, more cost-effective sequencingFull story -
Antibodies.com Raises £400,000 Pre-Seed Round to Help Researchers Discover More For Less
Jul 2, 2019, 05:27 AM by Michael Croft, CAMBRIDGE, UNITED KINGDOM - Jul 2, 2019 - Antibodies.com, a digital marketplace that enables life scientists to purchase critical research reagents at cost-effective prices from the primary manufacturers, today announced that is has raised £400,000 in pre-seed financingFull story -
LabTwin, AbCellera, X4, And More: News From June 2019
Jul 1, 2019, 10:05 AM by Michael CroftFull storyBio-IT World | June featured exciting new, products, and partnerships from around the bio-IT community from innovating companies, organizations, and universities, including LabTwin, AbCellera, X4, and more.
-
Creative Diagnostics Launches Viral Antigens for Science Community
Jul 1, 2019, 03:31 AM by Michael CroftSHIRLEY, NY, UNITED STATES - Jul 1, 2019 - As a global leading supplier of of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics announced that it has launched a series of viral antigens for biological research use, including Adenovirus, CMV, Coronavirus, Coxsackievirus, Dengue Virus, EBV, EV71, Ebola Virus, HAV, HBV and so onFull story -
Cofactor Joins FNIH Biomarkers Consortium to Add Predictive Immune Modeling Expertise as New Resource for Multidimensional Biomarker Discovery
Jun 28, 2019, 17:09 PM by Michael CroftBELFORD, NJ, US - Jun 28, 2019 - Cofactor Joins FNIH Biomarkers Consortium to Add Predictive Immune Modeling Expertise as New Resource for Multidimensional Biomarker Discovery-Contributing to both the Cancer and Inflammation and Immunity Steering Committees-SAN FRANCISCO--(BUSINESS WIRE)-- Cofactor Genomics, pioneers in the field of Predictive Immune Modeling, announced today that they have become a member of the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium with the goal of advancing the adoption of multidimensional biomarkers in cancer and immune-related diseasesFull story -
NEW MONOCLONAL ANTIBODY FOR RUBELLA TESTING AVAILABLE FROM BINDING SITE
Jun 28, 2019, 14:25 PM by Michael CroftSAN DIEGO - Jun 28, 2019 - ~~San Diego, CA . . . . BINDING SITE'sIMMUNOLOGICALS GROUP is pleased to announce the addition of a new, purified monoclonal antibody to be used for the analysis and testing of the RubellaFull story -
The RGC UK Biobank Consortium Data Delivery And Cohort Browser
Jun 28, 2019, 11:15 AM by Michael CroftFull storyBio-IT World | The Regeneron Genetics Center has undertaken the exome sequencing and analysis of 500,000 samples from the UK Biobank, using the DNAnexus Platform to host the dataset and run Regeneron’s software pipeline. To increase the value to the RGC UKB consortium, Regeneron and DNAnexus partnered to construct a combined database of the UKB genomic and phenotypic data to explore through an innovative user interface.
-
BOC Sciences Upgrades Its Product Line Specially Targeted for Life Science Research
Jun 26, 2019, 21:27 PM by Michael CroftSHIRLEY, NY, UNITED STATES - Jun 27, 2019 - As a well-established chemical supplier based in New York, BOC Sciences announces to upgrade one of its product lines specially targeted for life science research, including small molecules in stem cell, carbohydrates, nucleosides & nucleotides as well as fluorescent probesFull story -
AbbVie, Discngine Collaborate On Structure-Based Drug Discovery Explorer
Jun 26, 2019, 09:55 AM by Michael CroftFull storyBio-IT World | Although wildly used, rational structure-based drug design techniques are far from being applied to their fullest potential. AbbVie and Discngine addressed the pitfalls by co-developing a web-based structural knowledge management solution called 3decision.
-
X4 Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Mavorixafor for the Treatment of WHIM Syndrome
Jun 26, 2019, 09:02 AM by Michael CroftCAMBRIDGE, MA, US - Jun 26, 2019 - X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the initiation of 4WHIM, a pivotal Phase 3 global clinical trial of mavorixafor (X4P-001) for the treatment of WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, inherited, primary immunodeficiency diseaseFull story -
Creative Biolabs Provides Diabody Service to Customers for Research Use
Jun 26, 2019, 02:46 AM by Michael CroftACCORD, NY - Jun 25, 2019 - June 25, 2019, as one of the most successful suppliers in the field of antibody production, Creative Biolabs developed diabody service to customers for both academic and clinical research useFull story -
Genedata Expands Collaboration with AstraZeneca on Deep Learning for High-Content Image Analysis
Jun 25, 2019, 13:24 PM by Michael CroftBASEL, SWITZERLAND - Jun 25, 2019 - Genedata, a leading provider of advanced software solutions for biopharmaceutical R&D, today announced a collaboration with AstraZeneca to automate high-content screening (HCS) image analysis using Genedata Imagence®Full story -
LabTwin’s AI-powered Digital Assistant Now Talks Back and Connects Data Sources in the Lab with New Open API
Jun 25, 2019, 10:37 AM by Michael CroftBERLIN, N/A, GERMANY - Jun 3, 2019 - LabTwin GmbH, the world's first voice and AI-powered digital lab assistant, today announced its new open API that will connect scientists with data sources both inside and outside of the labFull story -
Certara Announces First Recipients of Certara-Monash University Industry Drug Development Fellowships
Jun 25, 2019, 09:43 AM by Michael CroftPRINCETON, NJ - Jun 25, 2019 - Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, and Monash University today announced the recipients of the inaugural Certara-Monash University Industry Drug Development Fellowships – DrFull story -
Sentieon's 'Faster/Cheaper' Genomics Tools
Jun 25, 2019, 08:50 AM by Michael CroftFull storyBio-IT World | Sentieon's DNAseq and TNseq software, are making waves in the life sciences, creating a "drop in replacement" that is a faster and cheaper alternative to the industry standard for secondary analysis in next-generation sequencing (NGS) data processing while producing the industry standard results.
-
Medherant positions itself for the next stage of its development with the appointment of a new CEO
Jun 25, 2019, 06:13 AM by Michael CroftCOVENTRY, UK - Jun 25, 2019 - Medherant Limited (Medherant), the clinical-stage company developing innovative products for pain and CNS diseases using a unique transdermal delivery technology, TEPI Patch®, has appointed John Burt as Chief Executive Officer, effective 24 June 2019Full story -
Creative Proteomics Has Launched a Wide Range of Newly-developed Proteomics Analysis Services for Biologists
Jun 25, 2019, 03:12 AM by Michael CroftSHIRLEY, NY, US - Jun 25, 2019 - Creative Proteomics, a leading supplier in metabolomics services, has recently released its several newly-developed proteomics services to researchersFull story